AYTU
AYTU BIOPHARMA, INC
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$1.96
−3.92%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$2.01
From 52W high−32.41%
Volume14390.00
Market cap$21.30M
P/E (TTM)—
P/S (TTM)0.4x
Div yield—
Key dataOct 19, 2026
Open
$2.01
From 52W high
−32.41%
Volume
14390.00
Market cap
$21.30M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.5x
P/E (TTM)
—
RSI (14)
44.5
MomentumView details →
1D Return
−3.92%
YTD Return
−21.73%
SummaryUpdated Jun 1, 2026
Aytu BioPharma, Inc. (NASDAQ:AYTU) is a specialty pharmaceutical company founded in 2015 and headquartered in Englewood, Colorado. Originally incorporated as Aytu BioScience, the company changed its name to Aytu BioPharma in March 2021. The company has undergone significant strategic transformation over recent years, evolving from a multi-segment operation with consumer health and clinical development programs into a focused specialty pharmaceutical company concentrating exclusively on commercializing prescription medications for ADHD and pediatric conditions.
Similar companies
Latest newsMore news →
Aytu BioPharma reported FY2026 net revenue of $57.6 million, down 13.3% year over year, with a net loss of $14.25 million.27d agoAytu BioPharma reported Q4 2026 net revenue of $16.1 million, up 6.4% year over year, and a net loss of less than $0.1 million.27d agoAytu BioPharma announced it will report its fiscal 2026 full year and fourth quarter operational and financial results after market close on September 22, 2026, with a conference call and webcast the same day.33d ago